-
6 days ago | 
parkinsonsnewstoday.com | Andrea Lobo
The Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program, which trains specialists in improving access to Parkinson’s disease care. The program provides funding each year for medical centers to train physicians to become Parkinson’s specialists. These movement disorder specialists are neurologists with additional training in diagnosing and treating Parkinson’s disease.
-
1 week ago | 
parkinsonsnewstoday.com | Andrea Lobo
The dysregulation of RNA editing within astrocytes (neuron-supporting cells) seems to induce chronic inflammation and ultimately contributes to the loss of nerve cells in people with Parkinson’s disease, according to a recent study. This dysregulation is triggered by alpha-synuclein clumping, which is a characteristic feature of Parkinson’s.
-
1 week ago | 
pulmonaryhypertensionnews.com | Andrea Lobo
Reducing the levels of the protein NEK2 in the pulmonary arteries lessened disease-driving changes in blood vessels and the heart of a rat model of pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD). The effects were tied to a modulation of the NF-kB pathway involved in vascular remodeling, a set of changes in blood vessels’ arrangement and structure that underlies PAH, the study found.
-
1 week ago | 
smanewstoday.com | Andrea Lobo
SMA Europe will host its 1st International Clinical Care Symposium on SMA and focus on the biological causes of spinal muscular atrophy (SMA) and how to prevent and manage the symptoms that may lead to life-threatening emergencies.
-
1 week ago | 
parkinsonsnewstoday.com | Andrea Lobo
Physical exercise, avoiding falls, and the importance of providing support to caregivers were the focus of the 10th UAMS Parkinson’s symposium hosted last month by the University of Arkansas for Medical Sciences (UAMS), where the latest advances in diagnosing and treating people with Parkinson’s disease and atypical parkinsonism were also shared.
-
1 week ago | 
cysticfibrosisnewstoday.com | Andrea Lobo
The Clairity Ball — the hallmark annual event of Claire’s Place Foundation — is set to return to Southern California later this month with an evening of fundraising that will bring together celebrities and champions of the cystic fibrosis (CF) community. The nonprofit’s May 31 ball, to be held at the Fairmont Miramar Hotel in Santa Monica, aims to raise funds to support children and families affected by CF.
-
1 week ago | 
parkinsonsnewstoday.com | Andrea Lobo
Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in people with Parkinson’s disease, according to data from a pilot Phase 2 clinical trial. In addition to significant reductions in depression and anxiety, results from the trial (NCT04932434) pointed to psilocybin’s potential benefits for patients’ cognitive and motor function.
-
1 week ago | 
sclerodermanews.com | Andrea Lobo
Wasting of the skeletal muscle, older age, being male, and having swollen joints are among the risk factors for primary heart involvement associated with systemic sclerosis (SSc), according to a study using a worldwide database.
-
1 week ago | 
fapnewstoday.com | Andrea Lobo
Sudoscan, a test used to indirectly assess small nerve fiber damage through sweat gland function, may be a marker of disease severity and progression in people with hereditary transthyretin (ATTRv) amyloidosis, a group of diseases that includes familial amyloid polyneuropathy (FAP).
-
1 week ago | 
parkinsonsnewstoday.com | Andrea Lobo
Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the company that also showed IC 100 was able to reduce alpha-synuclein aggregation, a hallmark of Parkinson’s disease that contributes to neurodegeneration.
